Syros Pharmaceuticals Financial Health

Short Term Liabilities: SYRS's short term assets ($252.3M) exceed its short term liabilities ($38.4M).

Long Term Liabilities: SYRS's short term assets ($252.3M) exceed its long term liabilities ($117.1M).

Debt Level: SYRS has more cash than its total debt.

Reducing Debt: SYRS's debt to equity ratio has increased from 0% to 31.4% over the past 5 years.

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SYRS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SYRS has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 19.4% each year.

• Healthy companies in the Pharmaceuticals & Biotech industry.